[Use of polyplatillen in chemotherapy of advanced pancreatic cancer].
The results of Poliplatillen clinical application in 108 patients with advanced pancreatic cancer were analyzed. The use of Poliplatillen in adjuvant regimen improves the long-term results of treatment. The mean survival time was increased on 2.9 months, which was statistically significant, mediana survival was increased on 1.5 months, 10% of patients alived 20 months, 20%--16 months. Survival of patients of control group did not exceed 12 months.
Iatsenko
L D
LD
Lial'kin
S A
SA
Maĭdanevych
N M
NM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D018736:DNA Adducts / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D018736:DNA Adducts; C057270:cisplatin-DNA adduct; D002945:Cisplatin